| Nasdaq: DNDN
Dendreon Corp. is a biotechnology company, which focuses on discovery, development and commercialization of novel therapeutics that improves cancer treatment options for patients. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA.